Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R<;SUP>;1<;/SUP>;, R<;SUP>;2<;/SUP>;, R<;SUP>;7<;/SUP>;, R<;SUP>;8<;/SUP>;, R<;SUP>;9 <;/SUP>;and R<;SUP>;10 <;/SUP>;are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.